The first China-discovered and developed treatment for colorectal cancer (CRC), fruquintinib, has won approval from the National Medical Products Administration of China, marking Hutchison China Meditech Ltd.'s (Chi-Med) first approval for an innovative medicine. The drug, a small-molecule inhibitor of VEGF receptors to be marketed as Elunate, is now approved for the treatment of metastatic CRC patients who have failed at least two prior systemic antineoplastic therapies.